




The relative strengths and weaknesses of Midatech Pharma US Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Midatech Pharma US Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Midatech Pharma US Inc is the variable Net Income, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 35% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	7,045
Cost of Goods Sold	0
Intangible Assets	4,530
Liabilities, Current	2,039
Liabilities, Non-Current	0
Other Assets	67
Other Compr. Net Income	45
Other Expenses	993
Other Liabilities	660
Other Net Income	-1,778
Other Revenues	54
Property and Equipment	50
Research and Development	2,735
Selling, General and Administrative Expense	4,663

Output Variable	Value in 1000 USD
Assets	11,692
Liabilities	2,699
Expenses	8,391
Revenues	54
Stockholders Equity	8,993
Net Income	-10,115
Comprehensive Net Income	-10,092
BaseVar	12,329
ECR before LimitedLiability	132%
Economic Capital Ratio	255%